These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
341 related articles for article (PubMed ID: 23266882)
1. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival. Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882 [TBL] [Abstract][Full Text] [Related]
2. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen. Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971 [TBL] [Abstract][Full Text] [Related]
3. Salvage chemotherapy with biweekly irinotecan, plus 5-fluorouracil and leucovorin in patients with advanced gastric cancer previously treated with fluoropyrimidine, platinum, and taxane. Sym SJ; Ryu MH; Lee JL; Chang HM; Kim TW; Lee SS; Lee JS; Kang YK Am J Clin Oncol; 2008 Apr; 31(2):151-6. PubMed ID: 18391599 [TBL] [Abstract][Full Text] [Related]
4. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane. Erdem GU; Bozkaya Y; Ozdemir NY; Demirci NS; Yazici O; Zengin N Bosn J Basic Med Sci; 2018 May; 18(2):170-177. PubMed ID: 28941466 [TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy with irinotecan, 5-fluorouracil and leucovorin for taxane- and cisplatin-refractory, metastatic gastric cancer. Kim ST; Kang WK; Kang JH; Park KW; Lee J; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Park YS; Im YH; Park K Br J Cancer; 2005 May; 92(10):1850-4. PubMed ID: 15870718 [TBL] [Abstract][Full Text] [Related]
6. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628 [TBL] [Abstract][Full Text] [Related]
7. FOLFIRI regimen in metastatic pancreatic adenocarcinoma resistant to gemcitabine and platinum-salts. Neuzillet C; Hentic O; Rousseau B; Rebours V; Bengrine-Lefèvre L; Bonnetain F; Lévy P; Raymond E; Ruszniewski P; Louvet C; Hammel P World J Gastroenterol; 2012 Sep; 18(33):4533-41. PubMed ID: 22969226 [TBL] [Abstract][Full Text] [Related]
8. Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients. Pasquini G; Vasile E; Caparello C; Vivaldi C; Musettini G; Lencioni M; Petrini I; Fornaro L; Falcone A Oncology; 2016; 91(6):311-316. PubMed ID: 27705972 [TBL] [Abstract][Full Text] [Related]
9. Phase II study of biweekly paclitaxel plus infusional 5-fluorouracil and leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Wang F; Wang Z; Zhou N; An X; Xu R; He Y; Li Y Am J Clin Oncol; 2011 Aug; 34(4):401-5. PubMed ID: 21791984 [TBL] [Abstract][Full Text] [Related]
10. Irinotecan combined with 5-fluorouracil and leucovorin as second-line chemotherapy for metastatic or relapsed gastric cancer. Seo MD; Lee KW; Lim JH; Yi HG; Kim DY; Oh DY; Kim JH; Im SA; Kim TY; Lee JS; Bang YJ Jpn J Clin Oncol; 2008 Sep; 38(9):589-95. PubMed ID: 18772169 [TBL] [Abstract][Full Text] [Related]
11. The efficacy and toxicity of irinotecan with leucovorin and bolus and continuous infusional 5-fluorouracil (FOLFIRI) as salvage therapy for patients with advanced gastric cancer previously treated with platinum and taxane-based chemotherapy regimens. Kaya AO; Coskun U; Gumus M; Dane F; Ozkan M; Isıkdogan A; Alkis N; Buyukberber S; Yumuk F; Budakoglu B; Demirci U; Berk V; Bilici A; Inal A; Arpacı E; Benekli M; J Chemother; 2012 Aug; 24(4):217-20. PubMed ID: 23040686 [TBL] [Abstract][Full Text] [Related]
12. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer. Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159 [TBL] [Abstract][Full Text] [Related]
13. A phase II study of irinotecan with bi-weekly, low-dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as salvage therapy for patients with advanced or metastatic gastric cancer. Kim SG; Oh SY; Kwon HC; Lee S; Kim JH; Kim SH; Kim HJ Jpn J Clin Oncol; 2007 Oct; 37(10):744-9. PubMed ID: 17923456 [TBL] [Abstract][Full Text] [Related]
14. Phase II trial of irinotecan plus oxaliplatin and 5-fluorouracil/leucovorin in patients with untreated metastatic gastric adenocarcinoma. Lee J; Kang WK; Kwon JM; Oh SY; Lee HR; Kim HJ; Park BB; Lim HY; Han MJ; Park JO; Park YS Ann Oncol; 2007 Jan; 18(1):88-92. PubMed ID: 16971670 [TBL] [Abstract][Full Text] [Related]
15. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Assersohn L; Brown G; Cunningham D; Ward C; Oates J; Waters JS; Hill ME; Norman AR Ann Oncol; 2004 Jan; 15(1):64-9. PubMed ID: 14679122 [TBL] [Abstract][Full Text] [Related]
16. Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice. Pistelli M; Scartozzi M; Bittoni A; Galizia E; Berardi R; Cascinu S Tumori; 2011; 97(3):275-9. PubMed ID: 21789002 [TBL] [Abstract][Full Text] [Related]
17. Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Aranda E; Valladares M; Martinez-Villacampa M; Benavides M; Gomez A; Massutti B; Marcuello E; Constenla M; Cámara JC; Carrato A; Dueñas R; Reboredo M; Navarro M; Díaz-Rubio E Ann Oncol; 2009 Feb; 20(2):251-7. PubMed ID: 18718892 [TBL] [Abstract][Full Text] [Related]
18. Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Xu RH; Muro K; Morita S; Iwasa S; Han SW; Wang W; Kotaka M; Nakamura M; Ahn JB; Deng YH; Kato T; Cho SH; Ba Y; Matsuoka H; Lee KW; Zhang T; Yamada Y; Sakamoto J; Park YS; Kim TW Lancet Oncol; 2018 May; 19(5):660-671. PubMed ID: 29555258 [TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of the efficacy and safety of oxaliplatin plus 5-fluorouracil/leucovorin (modified FOLFOX6) with advanced gastric cancer patients having a good or poor performance status. Hacibekiroglu I; Kodaz H; Erdogan B; Turkmen E; Esenkaya A; Uzunoglu S; Cicin I Asian Pac J Cancer Prev; 2015; 16(6):2355-9. PubMed ID: 25824764 [TBL] [Abstract][Full Text] [Related]
20. The influence of prior ramucirumab treatment on the clinical activity of FOLFIRI as third-line therapy in patients with metastatic gastric Cancer. Roviello G; Petrioli R; Rosellini P; Multari AG; Conca R; Paganini G; Chiriacò G; Aieta M Invest New Drugs; 2019 Jun; 37(3):524-530. PubMed ID: 30687871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]